Online citations, reference lists, and bibliographies.

The Therapeutic Effectiveness Of The Coadministration Of Weekly Risedronate And Proton Pump Inhibitor In Osteoporosis Treatment

M. Tanaka, S. Itoh, Taro Yoshioka, K. Yamashita
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This trial was conducted to investigate the long-term effects of proton pump inhibitor (PPI) coadministration on the efficacy of weekly risedronate treatment for osteoporosis. Ninety-six women over 50 years old with low bone mineral density (BMD) participated in this trial. Subjects were randomly divided into 2 groups: a 17.5 mg dose of sodium risedronate was administered weekly, with or without a daily 10 mg dose of sodium rabeprazole (n = 49 and 47 in the BP + PPI and BP groups, resp.). The following biomarkers were measured at the baseline and every 3 months: bone-specific alkaline phosphatase, N-terminal telopeptide of type I collagen corrected for creatinine, parathyroid hormone, BMD of the lumbar spine, and physical parameters evaluated according to the SF-36v2 Health Survey. Statistical comparisons of these parameters were performed after 6, 12, 18, and 24 months. The Δ values of improvement in physical functioning after 12 months and bodily pain after 6 and 12 months in the BP + PPI group were significantly larger than those in the BP group. These results suggest that PPI does not adversely affect bone metabolism. Alternatively, approved bone formation by concomitant PPI treatment may have had favorable effects on the improvement of bodily pain and physical functions.
This paper references
10.1210/JC.2006-1415
Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice.
W. Leslie (2007)
The effect of proton pump inhibitors on fracture risk: report from theCanadianMulticenterOsteoporosis Study
L.-A. Fraser (2013)
Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis
R. Rizzoli (1988)
10.1359/JBMR.2002.17.11.1988
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
R. Rizzoli (2002)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1007/s00198-012-2112-9
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study
L-A. Fraser (2012)
10.1016/j.bone.2013.10.017
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hiroshi Hagino (2014)
10.1007/s00774-012-0406-9
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis
S. Itoh (2012)
10.1001/JAMA.282.14.1344
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
S. Harris (1999)
10.1007/s00774-004-0509-z
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial
K. Kushida (2004)
The effects of risedronate administered in combinationwith a protonpump Journal of Osteoporosis 5 inhibitor for the treatment of osteoporosis
S. Itoh (2013)
10.1007/s00774-003-0458-y
Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies
Y. Ogura (2003)
10.1007/s001980050010
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
J. Reginster (2000)
10.1056/NEJM198708273170903
Gastrointestinal absorption of calcium from milk and calcium salts.
M. Sheikh (1987)
10.1007/s00774-006-0706-z
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen
H. Kishimoto (2006)
10.1007/s00774-005-0616-5
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study
S. Uchida (2005)
10.1359/JBMR.050610
Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk.
M. Ito (2005)
10.1016/0009-9236(95)90245-7
Studies of the oral bioavailability of alendronate
B. Gertz (1995)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar